An FDA advisory committee voted 8-8 Thursday over whether the agency should allow Sanofi and Lexicon Pharmaceuticals' Zynquista, or sotagliflozin, to reach the market. Results of three clinical trials involving nearly 3,000 type 1 diabetes patients showed that although the drug helped reduce blood glucose levels, blood pressure and weight, 3.2% of 1,748 patients developed diabetic ketoacidosis, compared with 0.4% of 1,229 patients on placebo.
FDA advisory panel split on sotagliflozin approval
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.